<DOC>
	<DOCNO>NCT01131689</DOCNO>
	<brief_summary>In preclinical study , 5-fluorouracil , one active metabolites S-1 , show synergistic effect sorafenib human colon carcinoma cell line . Therefore , sorafenib combine S-1 might effective treatment patient advance HCC sorafenib monotherapy . The investigator propose conduct phase I study determine maximal tolerate dose ( MTD ) S-1 combination fix dose sorafenib patient advance HCC</brief_summary>
	<brief_title>Trial S-1 Combination With Sorafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients histologically confirm hepatocellular carcinoma ( HCC ) combination radiologically compatible find HCC , alphafetoprotein &gt; 400ng/mL liver cirrhosis 2 . Inoperable disease define 1 . Localized disease portion liver dose allow possibility complete surgical removal tumor clear resection margin OR 2 . Presence extrahepatic disease OR 3 . Main portal vein hepatic vein involvement ( invasion tumor thrombus ) OR 4 . The HCC must amenable intraarterial therapy local ablative therapy 3 . Minimum life expectancy 12 week 4 . Age &gt; 18 year . 5 . ECOG Performance Status 01 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : 1 . Hemoglobin &gt; 9.0 g/dl 2 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 3 . Platelet count &gt; 75,000/Î¼l 4 . Total bilirubin &lt; 1.5 time upper limit normal 5 . ALT AST &lt; 5 x upper limit normal 6 . Albumin &gt; = 3g/dL 7 . PTINR/PTT &lt; 1.5 x upper limit normal 8 . Serum creatinine &lt; 1.5 x upper limit normal Creatinine clearance &gt; =50mL/min 7 . Signed date informed consent start specific protocol procedure . 1 . Decompensated cirrhosis stage C accord ChildPugh Classification 2 . Chemoembolization within 8 week inclusion 3 . Other concomitant anticancer agent , include Tamoxifen Interferon 4 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 5 . History HIV infection 6 . Active clinically serious infection ( &gt; grade 2 CTCAE version 3.0 ) 7 . Symptomatic metastatic brain meningeal tumor 8 . Patients seizure disorder require medication ( steroids antiepileptic ) 9 . History organ allograft 10 . Patients evidence history bleed diathesis 11 . Patients undergoing renal dialysis 12 . Radiotherapy study within 4 week start study drug . 13 . Major surgery within 4 week start study 14 . Autologous bone marrow transplant stem cell rescue within 4 month study 15 . Prior exposure study drug . 16 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial ( men least 3 month last administration study medication ) . 17 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 18 . Any condition unstable could jeopardize safety patient compliance study 19 . Patients unable swallow oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>metastatic HCC</keyword>
</DOC>